Market Overview:
The global dysautonomia treatment drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of dysautonomia, rising awareness about dysautonomia and its treatments, and technological advancements in the field of dysautonomia treatment drugs. Based on type, the global dysautonomia treatment drugs market is segmented into fludrocortisone, midodrine, beta-blocker, pyridostigmine, IV saline infusion therapy (ISIT), and others. Fludrocortisone held a dominant share in 2017 owing to its high efficacy in treating various types of autonomic dysfunction such as neurocardiogenic syncope (NCS), postural orthostatic tachycardia syndrome (POTS), familial dysautonomia (FD), multiple system atrophy (MSA) and pure autonomic failure. Midodrine is also expected to witness significant growth during the forecast period due to its growing use for treating NCS and POTS. Based on application, the global Dysautonomic Treatment Drugs Market is segmented into neurocardiogenic syncope (NCS), postural orthostatic tachycardia syndrome(POTS), familialdysontonmia(FD)multiple systematrophy(MSA)andpure autonomicfailure(PAF).
Product Definition:
Dysautonomia Treatment Drugs are used to treat the symptoms of dysautonomia. These drugs help to improve the function of the autonomic nervous system, which controls many of the body's involuntary processes. By improving autonomic function, these drugs can help to relieve symptoms such as lightheadedness, dizziness, and fainting.
Fludrocortisone:
Fludrocortisone is a type of corticosteroid. It is used to treat Addison's disease, Cushing syndrome, and other diseases that cause excessive glucocorticoid activity in the body. Fludrocortisone works by suppressing the production of cortisol which reduces the stress on adrenal glands.
Midodrine:
Midodrine is a medication used for the treatment of conditions such as dry mouth, difficulty in swallowing, and throat irritation caused by excess saliva. It is also used to treat heart failure and pulmonary edema. Dysautonomia Treatment Drugs market Midodrine drug has been approved by the Food and Drug Administration (FDA) for use in patients with severe symptoms of autonomic neuropathy.
Application Insights:
Neurocardiogenic syncope (NCS) held the largest market share in 2017 owing to its high prevalence and incidence rates. It is also considered as a diagnostic challenge for physicians due to lack of objective criteria. NCS is characterized by sudden onset of heart rate and blood pressure fluctuations during rest periods, which may lead to cardiac arrest orudden death.
The postural orthostatic tachycardia syndrome (POTS) segment is expected to grow at the fastest rate during the forecast period due largelyto increasing awareness about this condition among general population along with rising number of patients suffering from POTS across the globe. According to an article published by NCBI in 2018, it has been estimated that around 300,000 people are living with POTS worldwide while another million have been diagnosed but remain undiagnosed due largelyto lackof diagnosis facilities and appropriate healthcare professionals skilled in diagnosing this condition resultingin large-scale underdiagnosis & undertreatmentof this disorder globally.
Regional Analysis:
North America accounted for the largest share of global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of autonomic disorders are some factors responsible for its dominance. According to the American Heart Association (AHA), approximately 6 million people in U.S. alone suffer from NCBI are experiencing neurocardiogenic syncope (NCGS).
Growth Factors:
- Increasing prevalence of dysautonomia
- Growing awareness about dysautonomia and its treatment options
- Rising demand for better and more effective dysautonomia treatments
- Technological advancements in the field of dysautonomia treatment drugs 5. Growing number of clinical studies on new dysautonomia treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Dysautonomia Treatment Drugs Market Research Report
By Type
Fludrocortisone, Midodrine, Beta-Blocker, Pyridostigmine, IV Saline, Others
By Application
Neurocardiogenic Syncope (NCS), Postural Orthostatic Tachycardia Syndrome (POTS), Familial Dysautonomia (FD), Multiple System Atrophy (MSA), Pure Autonomic Failure
By Companies
Aspen Pharmacare, Bausch Health, Pfizer, AbbVie, Alpha Medical Manufacturers Limited, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Dysautonomia Treatment Drugs Market Report Segments:
The global Dysautonomia Treatment Drugs market is segmented on the basis of:
Types
Fludrocortisone, Midodrine, Beta-Blocker, Pyridostigmine, IV Saline, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Neurocardiogenic Syncope (NCS), Postural Orthostatic Tachycardia Syndrome (POTS), Familial Dysautonomia (FD), Multiple System Atrophy (MSA), Pure Autonomic Failure
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aspen Pharmacare
- Bausch Health
- Pfizer
- AbbVie
- Alpha Medical Manufacturers Limited
- Boehringer Ingelheim
Highlights of The Dysautonomia Treatment Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fludrocortisone
- Midodrine
- Beta-Blocker
- Pyridostigmine
- IV Saline
- Others
- By Application:
- Neurocardiogenic Syncope (NCS)
- Postural Orthostatic Tachycardia Syndrome (POTS)
- Familial Dysautonomia (FD)
- Multiple System Atrophy (MSA)
- Pure Autonomic Failure
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dysautonomia Treatment Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment drugs for dysautonomia will vary depending on the individual's specific symptoms and diagnosis. However, some common treatment drugs used to treat dysautonomia include antidepressants, anticonvulsants, and beta blockers.
Some of the major players in the dysautonomia treatment drugs market are Aspen Pharmacare, Bausch Health, Pfizer, AbbVie, Alpha Medical Manufacturers Limited, Boehringer Ingelheim.
The dysautonomia treatment drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dysautonomia Treatment Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dysautonomia Treatment Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dysautonomia Treatment Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Dysautonomia Treatment Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Dysautonomia Treatment Drugs Market Size & Forecast, 2018-2028
4.5.1 Dysautonomia Treatment Drugs Market Size and Y-o-Y Growth
4.5.2 Dysautonomia Treatment Drugs Market Absolute $ Opportunity
Chapter 5 Global Dysautonomia Treatment Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Dysautonomia Treatment Drugs Market Size Forecast by Type
5.2.1 Fludrocortisone
5.2.2 Midodrine
5.2.3 Beta-Blocker
5.2.4 Pyridostigmine
5.2.5 IV Saline
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Dysautonomia Treatment Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Dysautonomia Treatment Drugs Market Size Forecast by Applications
6.2.1 Neurocardiogenic Syncope (NCS)
6.2.2 Postural Orthostatic Tachycardia Syndrome (POTS)
6.2.3 Familial Dysautonomia (FD)
6.2.4 Multiple System Atrophy (MSA)
6.2.5 Pure Autonomic Failure
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Dysautonomia Treatment Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Dysautonomia Treatment Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Dysautonomia Treatment Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Dysautonomia Treatment Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Dysautonomia Treatment Drugs Market Size Forecast by Type
9.6.1 Fludrocortisone
9.6.2 Midodrine
9.6.3 Beta-Blocker
9.6.4 Pyridostigmine
9.6.5 IV Saline
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Dysautonomia Treatment Drugs Market Size Forecast by Applications
9.10.1 Neurocardiogenic Syncope (NCS)
9.10.2 Postural Orthostatic Tachycardia Syndrome (POTS)
9.10.3 Familial Dysautonomia (FD)
9.10.4 Multiple System Atrophy (MSA)
9.10.5 Pure Autonomic Failure
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Dysautonomia Treatment Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Dysautonomia Treatment Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Dysautonomia Treatment Drugs Market Size Forecast by Type
10.6.1 Fludrocortisone
10.6.2 Midodrine
10.6.3 Beta-Blocker
10.6.4 Pyridostigmine
10.6.5 IV Saline
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Dysautonomia Treatment Drugs Market Size Forecast by Applications
10.10.1 Neurocardiogenic Syncope (NCS)
10.10.2 Postural Orthostatic Tachycardia Syndrome (POTS)
10.10.3 Familial Dysautonomia (FD)
10.10.4 Multiple System Atrophy (MSA)
10.10.5 Pure Autonomic Failure
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Dysautonomia Treatment Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Dysautonomia Treatment Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Dysautonomia Treatment Drugs Market Size Forecast by Type
11.6.1 Fludrocortisone
11.6.2 Midodrine
11.6.3 Beta-Blocker
11.6.4 Pyridostigmine
11.6.5 IV Saline
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Dysautonomia Treatment Drugs Market Size Forecast by Applications
11.10.1 Neurocardiogenic Syncope (NCS)
11.10.2 Postural Orthostatic Tachycardia Syndrome (POTS)
11.10.3 Familial Dysautonomia (FD)
11.10.4 Multiple System Atrophy (MSA)
11.10.5 Pure Autonomic Failure
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Dysautonomia Treatment Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Dysautonomia Treatment Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Dysautonomia Treatment Drugs Market Size Forecast by Type
12.6.1 Fludrocortisone
12.6.2 Midodrine
12.6.3 Beta-Blocker
12.6.4 Pyridostigmine
12.6.5 IV Saline
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Dysautonomia Treatment Drugs Market Size Forecast by Applications
12.10.1 Neurocardiogenic Syncope (NCS)
12.10.2 Postural Orthostatic Tachycardia Syndrome (POTS)
12.10.3 Familial Dysautonomia (FD)
12.10.4 Multiple System Atrophy (MSA)
12.10.5 Pure Autonomic Failure
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Dysautonomia Treatment Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Dysautonomia Treatment Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Dysautonomia Treatment Drugs Market Size Forecast by Type
13.6.1 Fludrocortisone
13.6.2 Midodrine
13.6.3 Beta-Blocker
13.6.4 Pyridostigmine
13.6.5 IV Saline
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Dysautonomia Treatment Drugs Market Size Forecast by Applications
13.10.1 Neurocardiogenic Syncope (NCS)
13.10.2 Postural Orthostatic Tachycardia Syndrome (POTS)
13.10.3 Familial Dysautonomia (FD)
13.10.4 Multiple System Atrophy (MSA)
13.10.5 Pure Autonomic Failure
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Dysautonomia Treatment Drugs Market: Competitive Dashboard
14.2 Global Dysautonomia Treatment Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aspen Pharmacare
14.3.2 Bausch Health
14.3.3 Pfizer
14.3.4 AbbVie
14.3.5 Alpha Medical Manufacturers Limited
14.3.6 Boehringer Ingelheim
